Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
XLO Xilio Therapeutics
3.380-0.190-5.32%
Close
02/08 16:00 ET
3.3800.0000.00%
Post Mkt Price 02/08 17:01 ET
High
3.550
Open
3.550
Turnover
114.16K
Low
3.261
Pre Close
3.570
Volume
33.87K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
Xilio Therapeutics (NASDAQ:XLO) Price Target Lowered to $10.00 at Morgan Stanley
Xilio Therapeutics (NASDAQ:XLO – Get Rating) had its target price lowered by Morgan Stanley from $20.00 to $10.00 in a research report sent to investors on Friday morning, Benzinga reports. The broke
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNymox Pharmaceutical (NASDAQ:NYMX) shares rose 21.8% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $45.2 million. Brainstorm Cell (NASDAQ:BCLI
Xilio Therapeutics (NASDAQ:XLO) PT Lowered to $10.00
Xilio Therapeutics (NASDAQ:XLO – Get Rating) had its target price reduced by investment analysts at Morgan Stanley from $20.00 to $10.00 in a research report issued on Friday, Benzinga reports. The
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating
11:54 AM EST, 01/27/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Xilio Therapeutics Is Maintained at Overweight by Morgan Stanley
Xilio Therapeutics Price Target Cut to $10.00/Share From $20.00 by Morgan Stanley
Xilio Therapeutics Price Target Cut to $10.00/Share From $20.00 by Morgan Stanley
Xilio Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/27/2023 148.14% Morgan Stanley $20 → $10 Maintains Overweight 12/21/2022 73.7% Chardan Capital → $7 Ini
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10
Morgan Stanley analyst Michael Ulz maintains Xilio Therapeutics (NASDAQ:XLO) with a Overweight and lowers the price target from $20 to $10.
Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MicroAlgo Inc. (NASDAQ:MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement for up to $3.2 million.Akanda Corp. (NASDAQ:AKAN) gained 52% to $0.2980.B
Company Overview
More
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
CEO： Dr. Rene Russo, Pharm.D.
Market： NASDAQ
Listing Date： 10/22/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet